Abstract:
• A study of the coagulation parameters of 87 normal controls (ages 50 to 80) were compared with those of 33 patients with thrombotic stroke and 55 patients with diabetes mellitus of the same age distribution.
There were no significant differences when tested for the influence of sex or age. Twenty-seven tests of clotting were done on each specimen, a total of 4,725. Significant differences were detected between normals versus patients with thrombotic stroke (fibrinogen level, glass clotting time, silicone clotting time, heparin tolerance, platelet count and retarded thromboplastin generation time BaSO 4 1:50 dilution) and between normals versus patients with diabetes (prothrombin time, silicone clotting time, platelet count, thromboplastin generation time and retarded thromboplastin generation time) when subjected to computer analysis. The clinical significance of these differences is not of practical value in the diagnosis or as a guide to therapy for stroke.
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• It is well known that several coagulation factors increase in the blood of pregnant females. 1 The relative infrequency of thrombosis during pregnancy, however, indicates that an increase in the concentration of coagulation factors alone does not necessarily lead to enhanced clot formation. There is, however, an established relationship to fibrin formation and vascular disease. Reports of increased fibrin formation and antifibrinolytic activity have been made in patients with thrombotic cerebral vascular disease. 2 
Ettinger
3 suggested in his study of patients with nonhemorrhagic stroke that values of the tests for the clotting mechanism may differ significantly when old and young normals are compared.
Since there is an increase in vascular disease with age and in patients with diabetes mellitus, it became necessary first to determine if the values in the coagulation parameters did differ between young and old normals and then if these values differed in patients having sustained a thrombotic stroke or in patients with diabetes mellitus.
Methods
The subjects were divided into groups as follows:
(a) Normal elderly males and females aged 50 to 80 years. These were recruited from senior citizens organizations, the Anti-Coronary Club, and relatives and friends of laboratory personnel. None were patients in the hospital and all filled out a medical questionnaire From Cornell University Medical Center, 1300 York Avenue, New York, New York 10021.
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and were approved for inclusion in the study by one of our physicians. There were 49 males and 38 females.
(b) A group of 33 patients in the New York Hospital with recent thrombotic stroke. The majority of coagulation studies were done within one day to one week after stroke; the longest time was 12 days after stroke in one patient. No patients on anticoagulant therapy were included in the study.
(c) A group of 55 patients followed in the Diabetic Clinic of the New York Hospital. The age ranges were 50 to 70 years. The majority of these patients had controlled diabetes achieved by oral medication. Infection was not a problem in these patients.
Dilution curves for all the coagulation factors (II, V, VII-X, VIII) were made from a pool of plasmas from five males and five females under 30 years of age. The other groups were read as percent of normal from these curves.
The procedure used was as follows: Normals were instructed to come to the laboratory in the fasting state where all bloods were drawn by our own technician. Disposable equipment was used. The blood was distributed into silicone-coated tubes containing 9 ml blood to either 1.0 ml of 3.8% sodium citrate or 0.1M sodium oxalate. Bloods drawn from patients in the hospital or in the clinic were brought directly to the laboratory where they were processed within the hour. The samples were spun in the cold (4°C) and the plasma placed in the plastic tube in an ice bath. Plasmas were absorbed with barium sulfate* (50 mg/ml) or aluminum hydroxidet (0.02 ml/1 ml of plasma) immediately for the assays of Factor V and Factor VIII STROKE AND BLOOD COAGULATION and as a plasmatic reagent in the thromboplastin generation test. Samples of 2 ml of whole blood were distributed into three glass tubes and three silicone tubes. These were placed in a water bath at 37°C and the clotting times determined. Prothrombin consumption was determined by spinning the clotted blood in the glass tubes, and after one hour removing the serum and adding 0.05 ml of 0.1M sodium oxalate to 0.45 ml of the serum. This was incubated for another 30 minutes. A 1/10 dilution of this mixture was made with buffer (imidazole-saline pH 7.5) and the prothrombin complex 4 (Ware-Stregnell prothrombin-proconvertin) determined. Prothrombin times were done 5 (Link-Shapiro modification of Quick's test) using Simplastin as the thromboplastin. Factor VII-X 6 was determined using a Seitz filtered beef plasma as a substrate. Normal plasma and patients' plasma in several dilutions were added and the prothrombin time determined. 7 The results were read as "percent" from a dilution curve prepared from the pool of young normal plasmas. Factor II was determined as above except the substrate was prepared free of Factor II (a mixture of equal amounts of BaSO 4 adsorbed plasma and serum which was clotted in the presence of thromboplastin).
Factor V: Plasma from the pool of normals was aged until the prothrombin time was more than 30 seconds. This was frozen in aliquots and used as the substrate. Normal plasma and patients' plasma adsorbed with BaSO 4 in several dilutions, and the prothrombin time was determined. Factor VIII 8 was determined much the same as Factor V except plasma from a patient deficient in Factor VIII (antihemophilic globulin) was used as the substrate and an activated partial thromboplastin test was done. A suspension of Kaolin was the activating agent and a commercially available soybean phosphatide (asolectin) was used as the partial thromboplastin. Fibrinogen was determined quantitatively by the method of Hill and Trevorrow. 9 The retarded thromboplastin generation test was a modification of the Biggs and Douglas test 10 as described by Thompson and colleagues. 11 Oxalated plasma was adsorbed with barium sulfate as in the conventional test or with aluminum hydroxide to distinguish thromboplastin generation accelerator from Factor VIII. 12 Platelet counts were done using a phase contrast microscope 13 and the unopette. Recalcification times of platelet-rich plasma and platelet-poor plasma were performed using an equal quantity of 0.025M CaCl 2 . The heparin resistance test was performed by the method of Verstraete 14 and was always done in duplicate on freshly drawn samples.
STATISTICAL ANALYSIS
The mean, standard deviation, and standard error for each parameter were computed for all groups. Each group was then separated by sex and decade, and means, standard deviations and standard errors again were calculated. Certain tests were further analyzed as to the percentage which fell either plus or minus one or two standard deviations from the mean value.
On the computer an analysis was done first to test the significance of sex and coagulation parameters of normal versus stroke and normal versus diabetic. Then Fibrinogen, mg% Cx, SD-basedon 'control')
FIGURE 1
Mean and standard deviation for fibrinogen. Ordinate percent of cases for normal, stroke and diabetic patients.
the age and sex were combined in all groups and the groups were tested for significance for each coagulation test. 
Mean and standard deviation for thromboplastin generation test. Plasma absorbed with Al (OH) S and diluted 1:50. Ordinate percent of cases for normal, stroke and diabetic patients.
A total of 175 blood samples were drawn and 27 determinations were made of each sample; thus there were 4,725 results. These were coded and punched on computer cards and the means, standard deviations, and standard errors calculated. Comparisons of the means of each parameter were performed using the Student's t tests.
Results
Coagulation parameters of 87 normal males and females were compared to those of 33 patients with recent thrombotic stroke and 55 patients with diabetes mellitus.
The comparisons for age and sex showed no significant differences between normal males or females aged 50, 60 or 70 when compared to younger males or females (under 30). Among those with thrombotic stroke or diabetes mellitus there were no differences in coagulation parameters when correlated with age or sex. When these were then compared by groups, i.e., normal versus stroke and normal versus diabetics, certain differences became apparent.
As may be seen in table 1, there were significant differences between the three groups. Between the normals and the patients with thrombotic stroke, the values for the fibrinogen and platelet counts were higher in stroke patients (compared to normals), while the values for the clotting times in glass and silicone were "shorter" for the stroke patients compared to the normals. For the prothrombin time the significance was negative in that the clotting time was longer in patients with stroke. This, however, might reflect the inclusion of one patient who was in a terminal state. However, there was no evidence that this patient had disseminated intravascular coagulation. When the normals were compared to the group with diabetes, the clotting parameters with a highly significant difference were Factor II; silicone clotting times and the recalcification times were "shorter." When the data are presented to show the percentage of patients that are +1 to +2 SD from the mean normal, the distribution of the Gaussian curve for the stroke patients skews to the right (figs. 1 through 4). For fibrinogen, 35% of the diabetics are clustered about the mean while 23% of the stroke patients are clustered at +2 SD ( fig. 1 ).
THROMBOPLASTIN GENERATION TESTS
In the thromboplastin test using the patients' complete system including platelet extract, if normals were compared to stroke patients there was no difference. There were significant differences between the normals and diabetics (table 1) .
RETARDED GENERATION TESTS
Significant differences were detected between the normals in both study groups in the 1:50 dilution of barium sulfate ( fig. 2 ) and aluminum hydroxide ( fig. 3 ). For both tests more patients with stroke are found at two standard deviations from the mean (slower results in the stroke group in comparison with normals) than are diabetic or control patients. For platelet counts more patients with diabetes and stroke fell at two standard deviations from the mean than normals (fig. 4 ).
Discussion
In this study of coagulation parameters, significant differences were detected between normal controls, patients with thrombotic stroke and those with diabetes mellitus when subjected to computer analysis. In general the values fell between -2 and +2 SD from the normal. The clinical significance of these findings is of little practical value in either establishing the diagnosis, guiding the therapy of these disease states, or predicting a stroke, as these changes are probably produced by the stroke itself.
Since the majority of these clotting tests are dependent upon fibrin formation, the increases found among the stroke patients might be explained by the elevated fibrinogen levels. It has been suggested by Fletcher 15 that there is a fundamental abnormality in fibrin polymerization in patients with complications of atherosclerotic vascular disease. Among the patients with diabetes mellitus the differences are more significant and as yet unexplained.
